To compare the effect of oral iron given daily versus alternate day on blood parameters when given for treatment of iron deficiency anemia in adult patients with chronic kidney disease

The effect of daily versus alternate day oral iron supplementation on serum hepcidin in patients with chronic kidney disease - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/088746

Enrollment

100

Registered

2025-06-12

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N189- Chronic kidney disease, unspecified Health Condition 2: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Tablet ferrous sulphate 200 mg: Given once on alternate days (at 8 am) per oral for a total of 12 weeks Control Intervention1: Tablet Ferrous sulphate 200 mg: Given once daily (at 8 am)

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of any gender with chronic kidney disease stage KDIGO stage G3- G4 (eGFR between 15- 60 ml/min/1.73m by CKD EPI equation) 2. Serum ferritin less than 100 mcg/l OR Serum ferritin less than 200 mcg/l with transferrin saturation less than 20% within 4 weeks of inclusion in study 3. Willing to give informed consent

Exclusion criteria

Exclusion criteria: 1. Hb less than 9g/dl 2. Current or past use of oral/parenteral iron in last 3 months 3. Active or past malignancy 4. Suspected or proven autoimmune disease 5. Suspected or proven active glomerulonephritis or vasculitis 6. Suspected hemoglobinopathy 7. History suggestive of malabsorption or surgery predisposing to absorption abnormalities 8. History of gastrointestinal bleeding or peptic ulcer disease 9. Bleeding diathesis 10. Pregnant/lactating women

Design outcomes

Primary

Measure	Time frame
change in mean serum hepcidin between daily and alternate day oral iron supplementation armsTimepoint: 6 weeks	—

Secondary

Measure	Time frame
Change in transferrin saturation in CKD patients treated with daily versus alternate day oral ironTimepoint: 3,6,12 weeks;Change in ferritin in CKD patients treated with daily versus alternate day oral iron Timepoint: 3,6,12 weeks;Change in hemoglobin level in CKD patients treated with daily versus alternate day oral ironTimepoint: 3,6,12 weeks;change in mean serum hepcidin between daily and alternate day oral iron supplementation armsTimepoint: 12 weeks	—

Measure

Time frame

Change in transferrin saturation in CKD patients treated with daily versus alternate day oral ironTimepoint: 3,6,12 weeks;Change in ferritin in CKD patients treated with daily versus alternate day oral iron Timepoint: 3,6,12 weeks;Change in hemoglobin level in CKD patients treated with daily versus alternate day oral ironTimepoint: 3,6,12 weeks;change in mean serum hepcidin between daily and alternate day oral iron supplementation armsTimepoint: 12 weeks

—

Countries

India

Contacts

Public ContactPallavi Prasad

VMMC and Safdarjung Hospital New Delhi

pallaviprasad1986@gmail.com9899797701

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026